Literature DB >> 23814157

Personalized medicine: hype or reality.

Bruce A Chabner, Leif W Ellisen, A John Iafrate.   

Abstract

Entities:  

Mesh:

Year:  2013        PMID: 23814157      PMCID: PMC4063383          DOI: 10.1634/theoncologist.2013-0210

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


× No keyword cloud information.
  16 in total

Review 1.  Molecular prescreening to select patient population in early clinical trials.

Authors:  Jordi Rodón; Cristina Saura; Rodrigo Dienstmann; Ana Vivancos; Santiago Ramón y Cajal; José Baselga; Josep Tabernero
Journal:  Nat Rev Clin Oncol       Date:  2012-04-03       Impact factor: 66.675

2.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

3.  ROS1 rearrangements define a unique molecular class of lung cancers.

Authors:  Kristin Bergethon; Alice T Shaw; Sai-Hong Ignatius Ou; Ryohei Katayama; Christine M Lovly; Nerina T McDonald; Pierre P Massion; Christina Siwak-Tapp; Adriana Gonzalez; Rong Fang; Eugene J Mark; Julie M Batten; Haiquan Chen; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; David P Carbone; Hongbin Ji; Jeffrey A Engelman; Mari Mino-Kenudson; William Pao; A John Iafrate
Journal:  J Clin Oncol       Date:  2012-01-03       Impact factor: 44.544

4.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

5.  Imatinib targeting of KIT-mutant oncoprotein in melanoma.

Authors:  Xiaofeng Jiang; Jun Zhou; Noah K Yuen; Christopher L Corless; Michael C Heinrich; Jonathan A Fletcher; George D Demetri; Hans R Widlund; David E Fisher; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

6.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Kazuhiko Nakagawa; Takashi Seto; Lucio Crinó; Myung-Ju Ahn; Tommaso De Pas; Benjamin Besse; Benjamin J Solomon; Fiona Blackhall; Yi-Long Wu; Michael Thomas; Kenneth J O'Byrne; Denis Moro-Sibilot; D Ross Camidge; Tony Mok; Vera Hirsh; Gregory J Riely; Shrividya Iyer; Vanessa Tassell; Anna Polli; Keith D Wilner; Pasi A Jänne
Journal:  N Engl J Med       Date:  2013-06-01       Impact factor: 91.245

7.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

Review 8.  Translation of the Philadelphia chromosome into therapy for CML.

Authors:  Brian J Druker
Journal:  Blood       Date:  2008-12-15       Impact factor: 22.113

9.  Ponatinib in refractory Philadelphia chromosome-positive leukemias.

Authors:  Jorge E Cortes; Hagop Kantarjian; Neil P Shah; Dale Bixby; Michael J Mauro; Ian Flinn; Thomas O'Hare; Simin Hu; Narayana I Narasimhan; Victor M Rivera; Tim Clackson; Christopher D Turner; Frank G Haluska; Brian J Druker; Michael W N Deininger; Moshe Talpaz
Journal:  N Engl J Med       Date:  2012-11-29       Impact factor: 91.245

10.  Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.

Authors:  George Pentheroudakis; Vassiliki Kotoula; Wendy De Roock; George Kouvatseas; Pavlos Papakostas; Thomas Makatsoris; Demetris Papamichael; Ioannis Xanthakis; Joseph Sgouros; Despina Televantou; Georgia Kafiri; Athanassios C Tsamandas; Evangelia Razis; Eleni Galani; Dimitrios Bafaloukos; Ioannis Efstratiou; Iliada Bompolaki; Dimitrios Pectasides; Nicholas Pavlidis; Sabine Tejpar; George Fountzilas
Journal:  BMC Cancer       Date:  2013-02-02       Impact factor: 4.430

View more
  6 in total

1.  Allelic ratio of KRAS mutations in pancreatic cancer.

Authors:  Jochen K Lennerz; Albrecht Stenzinger
Journal:  Oncologist       Date:  2015-03-16

2.  Words matter: distinguishing "personalized medicine" and "biologically personalized therapeutics".

Authors:  Nathan I Cherny; Elisabeth G E de Vries; Linda Emanuel; Lesley Fallowfield; Prudence A Francis; Alberto Gabizon; Martine J Piccart; David Sidransky; Lior Soussan-Gutman; Chariklia Tziraki
Journal:  J Natl Cancer Inst       Date:  2014-10-07       Impact factor: 13.506

3.  Diagnostic Value of MAML2 Rearrangements in Mucoepidermoid Carcinoma.

Authors:  Julia C Thierauf; Alex A Farahani; B Iciar Indave; Adam Z Bard; Valerie A White; Cameron R Smith; Hetal Marble; Martin D Hyrcza; John K C Chan; Justin Bishop; Qiuying Shi; Kim Ely; Abbas Agaimy; Maria Martinez-Lage; Vania Nose; Miguel Rivera; Valentina Nardi; Dora Dias-Santagata; Salil Garg; Peter Sadow; Long P Le; William Faquin; Lauren L Ritterhouse; Ian A Cree; A John Iafrate; Jochen K Lennerz
Journal:  Int J Mol Sci       Date:  2022-04-13       Impact factor: 6.208

4.  Other side of the coin for personalised medicine and healthcare: content analysis of 'personalised' practices in the literature.

Authors:  Tomris Cesuroglu; Elena Syurina; Frans Feron; Anja Krumeich
Journal:  BMJ Open       Date:  2016-07-13       Impact factor: 2.692

5.  Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital.

Authors:  Aditya Bardia; John A Iafrate; Tilak Sundaresan; Jerry Younger; Valentina Nardi
Journal:  Oncologist       Date:  2016-08-22

6.  Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma.

Authors:  Julia Thierauf; Nisha Ramamurthy; Vickie Y Jo; Hayley Robinson; Ryan P Frazier; Jonathan Gonzalez; Maciej Pacula; Enrique Dominguez Meneses; Vania Nose; Valentina Nardi; Dora Dias-Santagata; Long P Le; Derrick T Lin; William C Faquin; Lori J Wirth; Jochen Hess; A John Iafrate; Jochen K Lennerz
Journal:  Oncologist       Date:  2019-03-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.